Health Care & Insurance  November 13, 2017

Array Biopharma releases results of clinical trials with Merck

BOULDER — Array Biopharma Inc. (Nasdaq: ARRY), a biopharmaceutical company focused on developing cancer therapies, announced data from one of its clinical trials.

The trial evaluated the immunotherapy combination of one of Array’s drugs, ARRY-382, with Merck’s Keytruda, an anti-PD1 antibody (a cell receptor important to regulating the immune system). The trial looked at patients with certain advanced solid tumors.

“We are pleased to announce the completion of the Phase 1b clinical study of ARRY-382 in combination with Keytruda,” Ron Squarer, Array’s chief executive, said in a prepared statement. “In addition to establishing an appropriate Phase 2 dose for the combination, we are encouraged by the early signs of activity in patients with tumor types that have been historically unresponsive to anti-PD1 therapies.”

SPONSORED CONTENT

Ways to thank a caregiver

If you have a caregiver or know someone who has been serving as a primary caregiver, March 3rd is the day to reach out and show them how much they are valued!

Nineteen patients were treated in the study. It included patients with pancreatic, colorectal, ovarian, gastric, melanoma and triple negative breast cancers.

The combination of the two drugs showed early signs of activity. Phase 2 of the study is active and enrolling patients.

 

BOULDER — Array Biopharma Inc. (Nasdaq: ARRY), a biopharmaceutical company focused on developing cancer therapies, announced data from one of its clinical trials.

The trial evaluated the immunotherapy combination of one of Array’s drugs, ARRY-382, with Merck’s Keytruda, an anti-PD1 antibody (a cell receptor important to regulating the immune system). The trial looked at patients with certain advanced solid tumors.

“We are pleased to announce the completion of the Phase 1b clinical study of ARRY-382 in combination with Keytruda,” Ron Squarer, Array’s chief executive, said in a prepared statement. “In addition to establishing an…

Sign up for BizWest Daily Alerts